Conference
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).
Abstract
186
Background: In men with mCRPC receiving chemotherapy, measurable disease response by World Health Organization criteria has been demonstrated to be prognostic for overall survival (OS). We aimed to explore the association of changes in measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) with OS. Methods: Data from the control arm (n=612) of the phase III VENICE trial receiving docetaxel plus …
Authors
Sonpavde G; Pond GR; Templeton AJ; Petrylak DP; Tombal BF; Rosenthal M; Tannock I
Volume
33
Pagination
pp. 186-186
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2015
DOI
10.1200/jco.2015.33.7_suppl.186
Conference proceedings
Journal of Clinical Oncology
Issue
7_suppl
ISSN
0732-183X